RxDoctor Payments Data

Arun Krishnamoorthy, MD

Advanced Heart Failure and Transplant Cardiology · Atlanta, GANPI 1144420712

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $25,050 of the $36,880 with a category attached, or 67.9%. Scpharmaceuticals Inc. accounts for 63.4% of it on its own, with 30 other manufacturers making up the rest.

$36,880in general payments, 2019–2025

Across 286 payments — averaging $128.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Scpharmaceuticals Inc.$23K
  • Novo Nordisk$5K
  • Novartis$3K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Abbott$1K
  • Pfizer$411
  • plus $2K from 25 others
$108,628in research payments, 2019–2025

Across 28 payments — averaging $3879.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • American Regent$40K
  • Merck$35K
  • Amgen$24K
  • Novartis$11K

What the payments were for

  • Consulting fees$6,00016%
  • Speaking & faculty fees$25,05068%
  • Travel & lodging$2011%
  • Food & beverage$5,59115%
  • Education$380%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,880 in reported general payments places this provider in the 70th percentile of 40 advanced heart failure and transplant cardiology providers in Georgia.

See all advanced heart failure and transplant cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$168,139
Medicare patients
332
Services billed
1,655

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis84$2,110,075
EntrestoSacubitril/Valsartan498$618,484
JardianceEmpagliflozin215$289,412
FarxigaDapagliflozin Propanediol175$199,868
EliquisApixaban121$131,912
CamzyosMavacamten12$85,233
FuroscixFurosemide12$77,165
VerquvoVericiguat41$37,820
WegovySemaglutide17$22,289
Tacrolimus38$11,380
TradjentaLinagliptin11$9,388
Atovaquone12$8,714
Sildenafil Citrate28$7,919
Valganciclovir Hcl22$5,266
Mycophenolate Mofetil19$3,752

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$411$2,241,987205 claims
NovartisEntresto$3,496$618,484498 claims
Boehringer IngelheimJardiance, Tradjenta$278$298,800226 claims
AstraZenecaFarxiga$200$199,868175 claims
E.r. Squibb & Sons, L.L.C.Camzyos$1,554$85,23312 claims
Scpharmaceuticals Inc.Furoscix$23,393$77,16512 claims
MerckVerquvo$344$37,82041 claims
Novo NordiskWegovy$4,759$22,28917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 40 advanced heart failure and transplant cardiology providers in Georgia.

Other advanced heart failure and transplant cardiology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →